ERLNC1: A Non-Coding RNA molecule as a Potential Drug Target and Biomarker

Target Name: ERLNC1

NCBI ID: G101929441

ERLNC1

Other Name(s): Estrogen receptor responsive lncRNA 1 | estrogen receptor responsive lncRNA 1 | ElncRNA1 | TC0101441

ERLNC1: A Non-Coding RNA molecule as a Potential Drug Target and Biomarker

Estrogen receptor responsive lncRNA (ERLNC1) is a non-coding RNA molecule that plays a critical role in the regulation of various cellular processes. It is a key regulator of gene expression, and its levels have been linked to various diseases, including cancer. ERLNC1 is a promising drug target and has been the focus of intense research in recent years.

Diseases associated with ERLNC1

ERLNC1 has been linked to various diseases, including breast cancer, ovarian cancer, and prostate cancer. These cancers are some of the leading causes of cancer-related deaths in women and men, respectively. ERLNC1 has also been associated with various other diseases, including cardiovascular disease, obesity, and neurodegenerative diseases.

ERLNC1 as a drug target

ERLNC1 has been identified as a potential drug target for various diseases, including breast and ovarian cancer. Several studies have shown that inhibiting ERLNC1 can lead to a reduction in the growth and survival of cancer cells.

One of the main reasons for the potential of ERLNC1 as a drug target is its involvement in the regulation of cell cycle progression. ERLNC1 has been shown to play a role in the regulation of the G1 phase of the cell cycle, which is critical for the growth and development of cancer cells. By inhibiting the activity of ERLNC1, researchers have shown that they can cause cancer cells to enter a state of G2/M phase, which can lead to the death of the cells.

Another potential mechanism by which ERLNC1 may be a drug target is its involvement in the regulation of cell adhesion. ERLNC1 has been shown to play a role in the regulation of cell-cell adhesion, which is critical for the development and maintenance of cancer stem cells. By inhibiting the activity of ERLNC1, researchers have shown that they can cause cancer cells to undergo a process of apoptosis, which can lead to the death of the cells.

ERLNC1 as a biomarker

ERLNC1 has also been shown to be a promising biomarker for various diseases, including breast and ovarian cancer. The levels of ERLNC1 have been shown to be elevated in cancer cells, and inhibiting the activity of ERLNC1 has been shown to lead to a reduction in the growth and survival of cancer cells.

Research has also shown that ERLNC1 can be used as a biomarker for other diseases, including cardiovascular disease and neurodegenerative diseases. For example, studies have shown that ERLNC1 levels are elevated in heart failure patient samples, and inhibiting the activity of ERLNC1 has been shown to lead to improved survival in these patients.

Conclusion

In conclusion, ERLNC1 is a non-coding RNA molecule that has been linked to various diseases, including cancer. Its levels have been shown to be elevated in cancer cells, and inhibiting the activity of ERLNC1 has been shown to lead to a reduction in the growth and survival of cancer cells. As a result, ERLNC1 is a promising drug target and has the potential to be used as a biomarker for various diseases. Further research is needed to fully understand the role of ERLNC1 in disease progression and its potential as a drug and biomarker.

Protein Name: Estrogen Receptor Responsive LncRNA 1

The "ERLNC1 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about ERLNC1 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets